AN2 Therapeutics director Robin Shane Readnour disposes of USD 212,486 common shares

Reuters2026/08/19 21:59

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

AN2 Therapeutics director Robin Shane Readnour reported sales of 35,402 common shares on Aug. 17.
Shares sold at a weighted average price of $6.01.
Indirect holdings stood at 565,592 shares via MGC Venture Partners 2018, LP.
Indirect holdings stood at 633,867 shares via MGC Venture Partners QP 2018, LP.
Readnour also held 9,077 shares directly following the transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AN2 Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-357225), on August 19, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

AN2 Therapeutics director Robin Shane Readnour disposes of USD 212,486 common shares

You may also like

Crypto prices